Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Biosimilars: SOP for Monitoring CO₂ Levels in Incubators – V 2.0

Posted on By


Biosimilars: SOP for Monitoring CO₂ Levels in Incubators – V 2.0


Standard Operating Procedure for Monitoring CO₂ Levels in Incubators in Biosimilar Labs

Department Biosimilars
SOP No. SOP/BS/045/2025
Supersedes SOP/BS/045/2022
Page No. Page 1 of 10
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To outline the routine procedure for monitoring and verifying carbon dioxide (CO₂) concentrations in cell culture incubators used in biosimilar development, ensuring optimal atmospheric conditions for cell growth and viability.

2. Scope

This SOP applies to all CO₂ incubators used in biosimilar R&D laboratories and cell line development areas where mammalian cells are cultured for biosimilar product development.

3. Responsibilities

  • Lab Technician: Conducts routine monitoring and records readings.
  • Engineering/Maintenance Staff: Performs calibration and adjustment of CO₂ sensors if deviations are detected.
  • QA Personnel: Reviews CO₂ monitoring records and verifies compliance.

4. Accountability

The Head of Biosimilar Manufacturing is accountable for ensuring the accuracy of CO₂ levels in all incubators used for critical cell culture operations.

5. Procedure

5.1 Monitoring Frequency and Instruments

  1. Monitor CO₂ levels in each incubator:
    • Daily visual check of digital CO₂ display
    • Weekly verification using a calibrated external CO₂ analyzer
  2. Ensure external analyzer is traceable and within calibration validity.

5.2 Daily Monitoring

  1. Record displayed CO₂ percentage in the Incubator CO₂ Log (Annexure-1).
  2. Expected range: 5.0% ± 0.2%
  3. If out of range, inform Engineering immediately and initiate deviation form.

5.3 Weekly Verification Using External Analyzer

  1. Place analyzer probe inside the incubator’s sample port or chamber.
  2. Allow reading to stabilize for 3–5 minutes.
  3. Record external analyzer reading and compare with incubator display.
  4. If deviation exceeds ±0.2%, initiate CO₂ calibration.

5.4 CO₂ Level Adjustment

  1. Adjust incubator CO₂ setpoint through the control panel following manufacturer’s guidelines.
  2. Re-verify after 15 minutes to confirm stabilization.
  3. Document adjustment in the CO₂ Correction Log (Annexure-2).

5.5 Gas Cylinder Management

  1. Ensure CO₂ gas cylinders are replaced before depletion (<20%).
  2. Record gas change in the CO₂ Gas Supply Log (Annexure-3).

5.6 Troubleshooting and Deviation Management

  1. Common issues:
    • Blocked gas inlet
    • Sensor drift or fault
    • Leak in CO₂ tubing
  2. Raise deviation report for any unresolved discrepancies and isolate incubator if required.

6. Abbreviations

  • CO₂: Carbon Dioxide
  • OOT: Out of Tolerance
  • QA: Quality Assurance

7. Documents

  1. Incubator CO₂ Log (Annexure-1)
  2. CO₂ Correction Log (Annexure-2)
  3. CO₂ Gas Supply Log (Annexure-3)

8. References

  • WHO TRS 1010 – GMP Equipment Guidelines
  • Manufacturer Manual for CO₂ Incubator (Model Specific)
  • ICH Q9 – Quality Risk Management

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Incubator CO₂ Log

Date Incubator ID CO₂ Display (%) Remarks Initials
04/05/2025 INC-CO2-01 5.1 Within limit AV

Annexure-2: CO₂ Correction Log

Date Incubator ID Observed Value (%) Corrected To (%) Adjusted By
03/05/2025 INC-CO2-02 4.7 5.0 Vinay Pawar

Annexure-3: CO₂ Gas Supply Log

Date Cylinder ID Replaced By Remaining Pressure Remarks
02/05/2025 CO2-2025-17 Sunita Reddy 18% New cylinder installed

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Included weekly analyzer verification and cylinder tracking Enhanced Monitoring
See also  Biosimilars: SOP for Audit Readiness of CLD Documentation - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: Analytical Method Development: Reagent Qualification for Method Development – V 2.0
Next Post: Aerosol: SOP for Validating Temperature Sensors in Aerosol Manufacturing – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version